Health Care • Biotechnology: Pharmaceutical Preparations
$0.99 ▼ -0.11
(-10.35%)
MKT CAP: $53.5M • VOL: 415.6K
52W L $0 52W H $1
ROARABLE / RQD
D • 47/100
PIOTROSKI
3 / 9
HOWL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$60.7M | -$73.6M | -$40.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$60.8M | -$70.5M | -$37.4M |
| EBITDA (Normalized) | -$60.7M | -$73.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$60.3M | -$56.2M | -$32.6M |
| Capital Expenditures (CapEx) | $0 | $254.0K | — |
| Free Cash Flow (FCF) | -$60.3M | -$56.4M | -$32.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $57.0M | $111.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $24.8M | $73.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HOWL.